A report questions the FDA's accelerated approval process citing Sarepta and Biogen therapies as examples. Read more here.

Alzheimer's disease is the most common type of dementia. Here, we break down what to know about this disease, including: What ...

The CHMP decision follows a similar verdict on Eisai and Biogen's first amyloid-targeting drug Aduhelm (aducanumab), which was approved in the US on a fairly controversial dataset, but later ...